Plasma Citrulline: A Marker for Monitoring & Quantifying Radiation-Induced Small Bowel Toxicity
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Small bowel irradiation results in epithelial cell loss and consequently impairs function and metabolism. A metabolic end product of small bowel enterocytes is plasma citrulline. The investigators evaluate the correlation between plasma citrulline level, dose-volume histogram of small bowel, and small bowel toxicity grade by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE ver.4.0) to investigate whether citrulline can be used as a biomarker for quantifying radiation-induced epithelial cell loss.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically confirmed cancer patients
Appropriate liver, renal, and bone marrow function for radiotherapy
Willing to provide informed written consent
At least 20 years old
prior abdominopelvic radiation therapy or chemotherapy or abdominal surgery
Any contraindication to radiotherapy (i.e. Severe connective tissue disorder, etc.)
Prior or simultaneous history of other malignancy
On medication for small bowel disease or CTCAE 4.0 Grade 1 or higher toxicity before radiation
Any treatment delay more than 1 week during radiotherapy
No radiotherapy due to any other reason except small bowel toxicity